Randomization is an important design feature, but the analyzed population still needs scrutiny. This open-label pilot illustrates both outcome uncertainty and the importance of participant flow. Primary study
What the trial found
The interim analysis included 49 hospitalized COVID-19 patients receiving thymalfasin plus standard care or standard care alone. Clinical-recovery estimates favored treatment numerically in both baseline oxygen-support categories, but neither comparison was statistically significant. A CD4-cell signal was observed in the low-flow subgroup. The full report describes exclusions after randomization, including a patient who died before the first treatment dose. Primary report
Our appraisal: analyze from the right starting point
Excluding someone because an event occurred before treatment began can change the question from the effect of assignment to the experience of selected treatment recipients. This does not automatically invalidate every analysis, but it requires a clear estimand and sensitivity checks. Death before first administration is especially relevant when interpreting recovery or mortality.
Subgroup estimates should retain their uncertainty. A favorable point estimate is not a confirmed benefit, while a broad interval is not proof of no effect. Small oxygen-support subgroups also make apparent differences between categories difficult to interpret reliably.
The immune-cell observation does not resolve the clinical endpoint uncertainty. A physiological response can motivate further research without proving that patients recover sooner. Readers should also distinguish an interim report from a completed, adequately powered confirmatory trial.
Before quantitative reuse, inspect all randomized-patient outcomes, exclusions, baseline oxygen balance, and the competing-risk definition of recovery. A transparent synthesis should describe what happened to participants who could no longer experience recovery, rather than treating them as ordinary missing observations. The appropriate conclusion is preliminary evidence with unresolved clinical effectiveness, not established COVID-19 benefit.
Frequently asked questions
Was this a blinded trial?
No; it was open-label.
Were 49 patients included in this analysis?
Yes.
Was clinical recovery conclusively improved?
No.
Did the report include an immune-cell signal?
Yes, in a baseline oxygen-support subgroup.
Were there exclusions after randomization?
Yes.
Why inspect a death before first treatment?
Its exclusion can affect the interpretation of assignment-based outcomes.
Does this report establish a treatment standard?
No.